A new open-access study has explored how cannabidiol (CBD) affects equine sarcoid cells in the laboratory, reporting changes in cell survival signals and in enzymes linked to tissue remodelling. The work adds to growing interest in whether CBD could have future roles in veterinary oncology, but the authors stress that this is early, in vitro research rather than evidence for treatment in horses.
Equine sarcoids are the most common skin tumour in horses. They are typically locally invasive rather than metastatic and are strongly associated with bovine papillomavirus (BPV).
What the researchers did
The team established three primary equine sarcoid cell lines and exposed them to CBD at several concentrations over time (6 to 72 hours). They assessed cell viability, cytotoxicity and apoptosis, then looked more closely at selected time points using an invasion assay and measurement of matrix metalloproteinases (MMP-1, MMP-2 and MMP-9), which are enzymes involved in extracellular matrix breakdown and tissue invasion.
They also ran reference work in normal equine dermal fibroblasts to check whether any effects looked tumour-specific rather than simply toxic to healthy skin cells.
Key findings
The study reported that CBD altered viability, cytotoxicity and apoptosis in sarcoid cells, with apoptosis increasing over time and marked cytotoxicity and reduced viability seen at the longest exposure (72 hours).
CBD also reduced levels of MMP-1, MMP-2 and MMP-9 in the culture medium under some conditions. Because MMP activity is linked to extracellular matrix remodelling and local invasiveness, this biochemical signal is of interest in a tumour type known for infiltrating surrounding tissue.
In functional testing, sarcoid cell invasiveness fell by around one-third to just under two-thirds after 24 hours depending on dose, but these changes were not statistically significant in this experiment.
In the normal dermal fibroblast reference tests, CBD did not reduce cell viability or impair migration under the study conditions, which the authors interpret as supportive of tumour-associated responsiveness rather than broad non-selective toxicity.
Why this matters, and what it does not mean
Sarcoids can be frustrating to manage because they vary widely in appearance and behaviour, and responses to treatment can be unpredictable. Any new avenue that might help clarify mechanisms of local invasion and tissue remodelling is worth exploring.
However, it is important to keep this in context. This was a laboratory study using isolated tumour cells, not a clinical trial in horses. It does not show that CBD is an effective or safe treatment for sarcoids in real-world cases, nor does it provide dosing guidance for horses.
What could come next
The authors conclude that their findings support further investigation of CBD’s role in extracellular matrix modulation in sarcoid tumours, likely including work across more sarcoid cell lines, additional models and, eventually, carefully designed in vivo research.
